-
Important news
-
News
-
Shenzhen
-
China
-
World
-
Opinion
-
Sports
-
Kaleidoscope
-
Photos
-
Business
-
Markets
-
Business/Markets
-
World Economy
-
Speak Shenzhen
-
Health
-
Leisure
-
Culture
-
Travel
-
Entertainment
-
Digital Paper
-
In-Depth
-
Weekend
-
Newsmaker
-
Lifestyle
-
Diversions
-
Movies
-
Hotels and Food
-
Special Report
-
Yes Teens!
-
News Picks
-
Tech and Science
-
Glamour
-
Campus
-
Budding Writers
-
Fun
-
Qianhai
-
Advertorial
-
CHTF Special
-
Futian Today
在线翻译:
szdaily -> Health -> 
US recommends Pfizer booster shot at 5 months
    2022-01-06  08:53    Shenzhen Daily

THE U.S. Centers for Disease Control and Prevention (CDC) announced Tuesday that people are now able to get a COVID-19 vaccine booster shot five months after receiving the second dose of the Pfizer-BioNTech primary series, shortening the waiting period by one month for those ages 12 and up.

The interval recommendation for people who received the Johnson & Johnson (J&J) Janssen vaccine is two months and six months for those who got the Moderna vaccine. The agency is also recommending that moderately or severely immunocompromised children ages 5-11 receive an additional primary dose of vaccine 28 days after getting their second shot.

Currently, only the Pfizer-BioNTech COVID-19 vaccine has been authorized and recommended for that age group.

“Today’s recommendations ensure people are able to get a boost of protection in the face of omicron and increasing cases across the country, and ensure that the most vulnerable children can get an additional dose to optimize protection against COVID-19,” CDC director Dr. Rochelle Walensky said in a statement.

The Advisory Committee on Immunization Practices (ACIP) was to meet Wednesday from 1 p.m. to 5 p.m. EST.

All of this comes after the Food and Drug Administration (FDA) authorized a third dose of the Pfizer-BioNTech vaccine for emergency use for children ages 12 to 15, shortened the period for booster shot eligibility to “at least five months,” and said it would allow a third primary series dose of the Pfizer vaccine for “certain immunocompromised children 5 through 11 years of age.”

“Peer-reviewed data from multiple laboratories indicate that a booster dose of the Pfizer-BioNTech COVID-19 vaccine greatly improves an individual’s antibody response to be able to counter the omicron variant,” the FDA wrote. Pfizer is studying its vaccine in even smaller doses, for children younger than 5.

(SD-Agencies)

深圳报业集团版权所有, 未经授权禁止复制; Copyright 2010-2020, All Rights Reserved.
Shenzhen Daily E-mail:szdaily@126.com